Recent advances in antituberculous drug development and novel drug targets.
Recent advances in antituberculous drug development and novel drug targets.
复制标题
DOI：
10.1586/17476348.2.4.455
复制
发表时间：
2008-08-01
影响因子：
3.9
通讯作者：
Shimizu, Toshiaki
中科院分区：
文献类型：
--
作者：
Tomioka, Haruaki;Tatano, Yutaka;Shimizu, Toshiaki
结核病，特别是耐多药结核病和广泛耐药结核病，是全球重要的健康问题，迫切需要开发有效的抗结核药物。新近阐明的关于结核分枝杆菌 (MTB) 整个基因组的关键信息以及有关各种分枝杆菌毒力基因的知识进展正在促进编码新药物靶点的基因鉴定的进展。在此背景下，本文主要从以下几个方面进行综述：一是根据MTB的潜在药理靶点，探讨抗结核新药的未来发展；其次，对抗结核新药的开发现状进行了综述，重点关注一些有前景的新型抗结核药物，如硝基咪唑类、二芳基喹啉类、恶唑烷酮类等。
TB, especially multidrug-resistant TB and extensively drug-resistant TB, is an important global health concern, and the novel development of effective anti-tuberculous drugs is urgently needed. Newly elucidated, critical information on the entire genome of Mycobacterium tuberculosis (MTB) and advances in knowledge regarding various mycobacterial virulence genes are promoting progression in the identification of genes that code for new drug targets. With this background, this review deals with the following areas: first, the future development of new anti-tuberculous drugs is discussed according to the potential pharmacological targets of MTB; and second, a review of the present development status of new anti-tuberculous drugs is conducted, particularly focusing on some promising new anti-tuberculous agents, such as nitroimidazoles, diarylquinolines and oxazolidinones.